Cellusion Inc.
Cellusion have developed three main technologies for solving global cornea shortage issue, which are novel cell transplantation method for Bullous Keratopathy treatment, mass production technology to produce corneal endothelial cell from iPS cells, spheroid transplantation method to enhance the treatment efficacy. With these cellular technology breakthroughs, we will contribute to provide the clear vision of the future for worldwide patients.
Business information
Company name
Cellusion Inc.
Established
2015
Location
Tokyo, JP
Spinout from
Other location(s)
Technology validation
TRL
5
Value of patent(s)
Business stage
Series A stage
Series B stage
Target exit
IPO in Japan
Trade sales
Next investment requirement
$2m to $3m
Message to the business partners
Cellusion always welcomes to join our team as whoever solving global blindness issue together. Regardless of collaboration or investment etc., please feel free to contact us. Why don’t we discuss what we can do together?
Company URL
Key literatures
To be updated